From: Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis
ASDAS-CRP | Â | Â | Â | Â | Â | Â | Â |
---|---|---|---|---|---|---|---|
1. Overall back pain (BASDAI question 2) | Â | Â | Â | Â | Â | Â | Â |
2. Global patient assessment | Â | Â | Â | Â | Â | Â | Â |
3. Peripheral pain/inflammation (BASDAI question 3) | Â | Â | Â | Â | Â | Â | Â |
4. Duration of morning stiffness (BASDAI question 6) | Â | Â | Â | Â | Â | Â | Â |
5. C-reactive protein (CRP) in mg/l [or erythrocyte sedimentation rate (ESR)] | Â | Â | Â | Â | Â | Â | Â |
ASDASCRP | 0.12 X overall |  +  | 0.06 X duration of |  +  | 0.07 X |  +  | 0.58 X |
---|---|---|---|---|---|---|---|
back pain | morning stiffness | Peripheral pain/inflammation | Ln(CRP + 1) | ||||
ASDASCRP < 1.3 | Activity = Inactive |  |  |  |  |  |  |
1.3 ≤ ASDASCRP < 2.1 | Activity = Low disease activity |  |  |  |  |  |  |
2.1 ≤ ASDASCRP < 3.5 | Activity = High |  |  |  |  |  |  |
ASDASCRP > 3.5 | Activity = Very high |  |  |  |  |  |  |